Abstract
Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed.
Publication Date
12-22-2019
First Page
e277
Last Page
283
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Al-Dughaishi, Malika; Shalaby, Asem; Al-Ribkhi, Khawla; Boudaka, Ammar; Boulassel, Mohamed-Rachid; and Saleh, Jumana
(2019)
"The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy,"
Sultan Qaboos University Medical Journal: Vol. 19: e277-283.
DOI: https://doi.org/10.18295/squmj.2019.19.04.002
